Regulatory Filings • Dec 8, 2017
Regulatory Filings
Open in ViewerOpens in native device viewer
Press release
Paris (France), December 8th , 2017, 7.30am - BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, announced today that four posters on Sarconeos (BIO101), the Company's clinical stage drug candidate for the treatment of sarcopenia, will be presented at the 10th International Conference on Cachexia, Sarcopenia and Wasting Disorders, being held December 8-10, 2017 in Rome, Italy.
Stanislas Veillet, CEO of Biophytis, comments: "We are pleased to participate once again to the International Conference on Cachexia, Sarcopenia and Wasting Disorders(SCWD). Because this conference gathers key opinion leaders in muscular dystrophies with the objective to raise awareness and deepen research on these indications, it represents a tremendous opportunity to review the clinical development of our drug candidate Sarconeos and patient outcomes observed to date."
| Posters: | |
|---|---|
| Title: | BIO103, a drug candidate for the treatment of muscle wasting disorders. |
| Authors: | Serova M., Didry-Barca, B., On S., Foucault A.S., Raynal S., On S., Veillet S., Dilda P.J., Lafont R. (2017). |
| Title: | SARA clinical program for evaluating safety and efficacy of Sarconeos in a Phase 2b clinical trial. |
| Authors: | Dioh W., Margalef C., Dupont P., Dilda P.J., Lafont R., Veillet S., Del Signore S. (2017). |
| Title: | SARA-data platform: Clinical Trials Novel Methodologies and Big Data to evaluate |
| SARconeos in Age-related sarcopenia. | |
| Authors: | Del Signore S., Zia G., Del Signore S., Dioh W. (2017). |
| Title: | Integrated, real-time ICT Platform for the SARA interventional Clinical Trial in Age related SARcopenia. |
| Authors: | Del Signore S., Dioh W., Del Signore S., Zia G. (2017). |
****
The Society on Sarcopenia, Cachexia and Wasting Disorders was founded in 2008 on the initiative of Dr. Stefan D. Anker and Dr. John E. Morley, whose leadership and vision guided the expansion of clinical expertise and research in this field. The Society on Sarcopenia, Cachexia and Wasting Disorders is a non-profit scientific organization comprised of an international and multidisciplinary group of health-care professionals primarily active in these fields. The SCWD seeks to further research on cachexia and sarcopenia and wasting disorders and bring practical solutions to health-care teams worldwide grappling with treatment. The spectrum of clinical disorders represented by the SCWD Society includes, but is not limited to cachexia, sarcopenia, the syndrome of muscle wasting associated to cancer, COPD, diabetes, heart failure, aging and other chronic conditions. In recent years, there has been tremendous growth in new diagnostic information, pharmacological and nutritional treatments for wasting disorders, as well as a greater number of associated clinical trials.
Sarconeos is a first-in-class drug candidate based on the activation of the MAS receptor (major player of the renin-angiotensin system) restoring muscular anabolism, inhibiting myostatin, and that had demonstrated meaningful activity in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle, leading to loss of mobility in elderly people. This condition, for which no medical treatment currently exists, was first described in 1993 and has entered the International Classification of Diseases (M62.84) in 2016. It affects more than 50 million people worldwide.
Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).
The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory.
The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.
BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS; ISIN: FR0012816825).
For more information: http://www.biophytis.com
Follow us on Twitter @biophytis
BIOPHYTIS is eligible for the SMEs scheme
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.
BIOPHYTIS Stanislas VEILLET CEO [email protected] Tel: +33 (0) 1 44 27 23 00 Citigate Dewe Rogerson International media & Investors Laurence BAULT/Antoine DENRY [email protected] [email protected] Tel: +33 (0)1 53 32 84 78 Mob: +33(0)6 64 12 53 61
LifeSci Advisors Chris MAGGOS Managing Director, Europe [email protected] Tel: +41 79 367 6254
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.